摘要
目的观察EPOCH方案治疗复发耐药中高度恶性非何杰金氏淋巴瘤(NHL)的疗效和不良反应。方法2002年12月至2004年12月我院收治复发耐药NHL17例,用VP-1650mg/m2/d、ADM或THP10mg/m2/d、VCR0.4mg/m2/d持续静脉滴注第1~4天,CTX750mg/m2/d静注第5天,强的松60mg/m2/d口服第1~5天,21天为一个疗程。结果本组17例均可评价疗效和不良反应,总有效率58.8%,完全缓解率(CR)23.5%,部分缓解率(PR)35.3%。主要不良反应为骨髓抑制,其他不良反应少见。结论EPOCH方案是复发耐药中高度恶性NHL经济有效的治疗方案,毒性可耐受。
Objective To evaluate the efficacy and toxicity of EPOCH regimen in patients with relapsed or refractory non- Hodgkin's lymphoma(NHL). Methods All 17 patients were treated with EPOCH regimen, VP-16 50mg/m^2/d、ADM or THP10mg/m^2/d、VCR0.4mg/m^2/d , CIV on days 1~4,CTX750mg/m^2/d iv on day 5,Pred 60mg/m^2/d on days 1~5, every 21 days. Results All the 17 patients were assessable. The overall response rate was 58.8%, CR 23.5%, PR 35.3% .Major toxicity was myelosuppression. Other toxicities were mild. Concusion EPOCH is effective and well tolerant for the patients with relapsed or refractory non- Hodgkin's lymphoma.
出处
《现代肿瘤医学》
CAS
2005年第4期528-529,共2页
Journal of Modern Oncology
关键词
非何杰金氏淋巴瘤
联合化疗
持续滴注
non- Hodgkin's lymphoma
combined chemotherapy
continuous infusion